Vitenskapelige publikasjoner

I 2016 hadde SESAM 40 publikasjoner i ulike tidsskrifter – 5 stk er nivå 2 publikasjoner

Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movment Disorder, 31(8), 1203-1208. Nivå 1

Alme KN, Engelsen BA, Naik M, Naess H.
Identifying patients at risk of acute symptomatic seizure after ischemic stroke. Acta Neurologica Scandinavica. [Epub ahead of print] Nivå 1

Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD - A factorial cluster randomised controlled trial. International Journal of Geriatric Psychiatry. Nivå 1


Bjerkreim AT, Thomassen L, Waje-Andreassen U, Selvik HA, Naess H.
Hospital Readmission after Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 25(1), 157-162. Nivå 1

A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease. Alzheimer’s research & therapy, 8(3), 1. Nivå 2

U-curve relation between cholesterol and prior ischemic stroke. Brain and Behavior, 6(11):e00574. Nivå 1

Brønnick K, Breitve MH, Rongve A, Aarsland D

Chong JR, Chai YL, Lee JH, Howlett D, Attems J, Ballard CG, Aarsland D, Francis PT, Chen CP, Lai MK.
Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load. Journal of Alzheimer’s disease [Epub ahead of print]. Nivå 1

Corbett A, Nunez KM, Smeaton E, Testad I, Thomas AJ, Closs SJ, Briggs M, Gjestesen MT, Lawrence V.
Enache D, Solomon A, Cavallin L, Kareholt I, Kramberger MG, Aarsland D, Kivipelto M, Eriksdotter M, Winblad B, Jelic V.
CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. *Neurobiology of Aging*, 42, 124-31. Nivå 1


Fromm A, Haaland OA, Naess H, Thomassen L, Waje-Andreassen U.

Hessen E, Stav AL, Auning E, Selnes P, Blomsø L, Holmeide CE, Johansen KK, Eliassen CF, Reinvang I, Fladby T, Aarsland D.
Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer’s and Parkinson’s Diseases. *Journal of Parkinson’s Disease*, 6(2). 413-421. Nivå 1

Kjosavik SR, Gillam MH, Roughhead EE.
Average duration of treatment with antidepressants among concession card holders in Australia. *The Australian and New Zealand journal of psychiatry*, 50(12),1180-5. Nivå 1


Novotny V, Khanevski AN, Thomassen L, Waje-Andreassen U, Naess H.

Novotny V, Thomassen L, Waje-Andreassen U, Naess H.

Oppedal K, Engan K, Eftestol TC, Beyer MK, Aarsland D.
Classifying Alzheimer’s disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. *Biomedical Signal Processing and Control*, 33 (Suppl), 19-29. Nivå 1

Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. Nivå 1
Romi F, Naess H.

Rongve A, Ballard C, Aarsland D.

Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. *BMJ open*, 6(2), e010357. Nivå 1

Sand KM, Naess H, Nilsen RM, Thomassen L, Hoff JM.


Sandvik RK, Selbaek G, Bergh S, Aarsland D, Husebo BS.
Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. *Journal of the American Medical Directors Association*. Nivå 1

Sandvik R, Selbaek G, Kirkevold O, Husebo BS, Aarsland, D.
Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 201: trend analyses of four data samples. *Age and Ageing*, 45(1), 54-60. Nivå 1

Selbaek G, Aarsland D, Ballard C, Engedal K, Langballe EM, Bent JŠ, Bergh S.
Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. *Journal of the American Medical Directors Association*, 17(5), 464. Nivå 1

Svendsboe E, Terum T, Testad I, Aarsland D, Ulstein I, Corbett A, Rongve A.
Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer’s disease. *International journal of geriatric psychiatry*, 31(9), 1075-1083. Nivå 1

Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers. *Journal of Alzheimer’s Disease*, 53(2), 621-630. Nivå 1


Testad I, Mekki TE, Forland O, Oye C, Tveit EM, Jacobsen F, Kirkevold Ø.
Modeling and evaluating evidence-based continuing education program in nursing home dementia care (MEDCED)-training of care home staff to reduce use of restraint in care home
Residents with dementia. A cluster randomized controlled trial. *International journal of geriatric psychiatry*, 31(1), 24-32. Nivå 1


Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, Francis PT, Chen CP, Lai MK. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. *Molecular Brain*, 9(1), 84. Nivå 1
